🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Novel targets and treatment developments in metastatic hormone-sensitive #ProstateCancer. Rashid K. Sayyid USC and Zach Klaassen Georgia Cancer Center discuss on UroToday > bit.ly/47AvQJR

Can mpMRI replace TURBT for faster treatment in MIBC? A randomized study shows that the mpMRI-first approach reduced the time to treatment by 45 days (53 vs. 98 days). No harm to non-MIBC patients. A game-changer for staging? #BladderCancer #MRI #Oncology ASCO Journal of Clinical Oncology

Very important comments, thank you Bishal Gyawali, MD, PhD, FASCO and Abhenil Mittal for bringing up these very important issues related to control arm in ARANOTE trial

Ever wondered why the results of 3 immunotherapy trials in urothelial cancers are different? Is it truly because the 3 drugs are different? In this smart study led by Tomer Meirson , we show that these differences can all be explained by differential censoring alone!

Our paper on IO combinations in metastatic translocation RCC is now online. Great collaborative work and addition to treatment outcomes in this rare entity. journals.lww.com/immunotherapy-… nirm Sumanta K. Pal, MD, FASCO Ritesh Kotecha Matthew Zibelman

Huge congrats to the super team of David Braun Toni Choueiri, MD & others that generated this phenomenal work published today in nature! An exciting leap forward in #kidneycancer.

#GU25: Key #bladdercancer presentations (in my opinion)- highlights and summary coming after the conference from AdventHealth Central Florida #cancer Institute- please note OncoAlert LARVOL OncLive.com GU Oncology Now SWOG Cancer Research Network Research To Practice PeerView Doximity

The future state of factors used in decision making in mHSPC -- based on molecular characteristics Tanya Dorff UroToday.com #GU25

Comparison of Adjuvant regimens for cancer across tumor types #GU25. Nivolumab per Checkmate 274 for #bladdercancer rises to the top. docs.google.com/presentation...

👏 Huge congrats to Pavlos Msaouel and team on this important work in Clinical Cancer Research! I’ve used CA-125 in practice—it’s a useful biomarker in RMC and can indicate response even before rapid progression on CT scan. 🔗 Read more: aacrjournals.org/clincancerres/… #KidneyCancer

Challenges in the Management of Advanced Prostate Cancer | JCO Oncology Practice Thank you Neeraj Agarwal, MD, FASCO and team for the excellent editorial OncoAlert Journal of Clinical Oncology ascopubs.org/doi/10.1200/OP…

⚡️ Circulating tumor DNA in muscle-invasive bladder cancer: A systematic review #BladderCancer EAU YAU Urothelial Carcinoma sciencedirect.com/science/articl…

Highly encourage everyone to peruse this terrific review in European Urology from the stellar team of Neeraj Agarwal, MD, FASCO Huntsman Cancer Institute, with lead authors Chadi Hage Chehade & Zeynep Irem Ozay, MD. I always appreciate their ability to distill complex data landscapes in thoughtful figures & tables, as you

Adrenocortical carcinoma: a practical guide for clinicians 💥A great guide that must be on the reading list for those interested in the topic or in need of practical information👇 thelancet.com/journals/landi…

Platinum Priority Review: Intensification Approaches and Treatment Sequencing in Metastatic Castration-resistant Prostate Cancer: A Systematic Review by Edoardo Francini et al Read the full article here: buff.ly/Refcr5K #UroSoMe #Urology #Spotlight #EURUROL #PCa

Rethinking Post-Chemo Surgery in NSGCT: 🔘Mass size alone isn’t enough to decide on RPLND after chemotherapy. 🔘Teratoma or yolk sac tumor in orchiectomy significantly raises the risk of residual disease. Annals of Oncology Tom Powles ESMO - Eur. Oncology European Association of Urology (EAU) OncoAlert

20 years ago, metastatic melanoma meant death in a year. Today? 🔸 10-yr Overall Survival: 43% (nivo+ipi) 🔸 10-yr Melanoma-Specific Survival: 52% This isn’t improvement. It’s a revolution. Believe in science. #Melanoma #Immunotherapy #Oncology #Cancer NEJM @asco ESMO - Eur. Oncology

Lines of Therapy for Locally Advanced/Metastatic Urothelial Carcinoma: The New Paradigm 🌟 ascopubs.org/doi/pdf/10.120… JCO Oncology Practice

Check our manuscript just published at The Oncologist Clinical & pathological outcomes of pts undergoing consolidative CN after ICI-based therapy for met / locally advanced RCC. Link: academic.oup.com/oncolo/article… Brian Rini, MD Katy Beckermann Sam S. Chang MD, MBA Daniel Barocas Amy Luckenbaugh

🧩 ctDNA is a key piece of the puzzle in building an integrated precision oncology ecosystem at Weill Cornell Medicine Excited to share collaborative paper #2 this month. This time with the brilliant Alexandre Pellan Cheng & Dan Landau! rdcu.be/ehkUb Nature Methods Highlights: 🔬